Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenues        
Products $ 271 $ 52 $ 554 $ 476
Services 669 819 2,073 2,531
Total Revenues 940 871 2,627 3,007
Cost of Revenues        
Products 107 94 259 410
Services 191 173 559 580
Total Cost of Revenues 298 267 818 990
Gross Profit 642 604 1,809 2,017
Operating Expenses        
Research and development 296 224 820 713
Sales and marketing 447 441 1,259 1,917
General and administrative 2,326 3,239 8,796 8,325
Acquisition related costs 78 94 5
Impairment of goodwill 587 587
Amortization of intangibles 812 808 2,419 2,536
Total Operating Expenses 3,959 5,299 13,388 14,083
Loss from Operations (3,317) (4,695) (11,579) (12,066)
Other Income (Expense)        
Interest expense (78) (252) (981) (1,317)
Change in fair value of derivative liability 46 48 254
Gain on the sale of Sysorex Arabia 23
Other income/(expense) 14 (11) (54)
Total Other Income (Expense) (78) (192) (921) (1,117)
Net Loss from Continuing Operations (3,395) (4,887) (12,500) (13,183)
Loss from Discontinued Operations, Net of Tax (1,785) (9,754) (4,778) (13,946)
Net Loss (5,180) (14,641) (17,278) (27,129)
Net Loss Attributable to Non-controlling Interest 4 (4) 6 (13)
Net Loss Attributable to Stockholders of Inpixon (5,184) (14,637) (17,284) (27,116)
Deemed dividend to preferred stockholders (11,235)
Net Loss Attributable to Common Stockholders $ (5,184) $ (14,637) $ (28,519) $ (27,116)
Net Loss Per Basic and Diluted Common Share        
Loss from continuing operations $ (3.17) $ (620.65) $ (45.97) $ (3,372.47)
Loss from discontinued operations (1.67) (1,238.76) (9.25) (3,567.66)
Net Loss Per Share - Basic and Diluted $ (4.84) $ (1,858.90) $ (55.24) $ (6,936.81)
Weighted Average Shares Outstanding        
Basic and Diluted 1,071,310 7,874 516,302 3,909